Treximet ™ Pharmacy Budget Impact Model Database Validation Study
NCT ID: NCT01332500
Last Updated: 2017-05-30
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
61737 participants
OBSERVATIONAL
2009-07-31
2010-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The SourceLx dataset from the family of Wolters Kluwer databases was used for this analysis. The database contains 30% of prescription claims filled in the United States (US), approximately 160 million patient lives. The data has broad representative coverage at both the geographic and payment levels.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treximet in the Treatment of Chronic Migraine
NCT01090050
A Pharmacokinetic Study to Evaluate TREXIMET in Adolescents With Migraine and Healthy Subjects Administered at Three Doses.
NCT00989625
TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults
NCT00573170
To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migraine Headaches
NCT00433732
A Combination Product of Sumatriptan and Naproxen Sodium Versus Single-entity Oral Triptans: An Analysis of Real World Data
NCT01381523
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
adult migraineurs with/without aura
Adult migraine patients \>18-65 years who have initiated treatment for migraine with Treximet ™ or other orally administered triptan.
Sumatriptan/Naproxen combination
Sumatriptan and Naproxen Sodium
other oral triptans
almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sumatriptan/Naproxen combination
Sumatriptan and Naproxen Sodium
other oral triptans
almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* at least 18 years of age at index Rx date
* at least one prescription claim for any medication in the pre- and post-index period (proxy for continuous enrollment)
Exclusion Criteria
* Subjects over 65 years of age
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
111208
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.